Siew Chin

Featured in: Favicon

frontiersin.org Favicon

biomedcentral.com (+2) Favicon

Articles

Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review - Health Economics Review

Jul 5, 2024 | healtheconomicsreview.biomedcentral.com | Siew Chin |Kunming City |Universiti Sains Malaysia |Technological Achievements |Hongyu Gong |Siew Chin Ong | +6 more

This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement (Supplementary Table 1) [26]. The systematic review was registered on the international prospective register of systematic reviews (PROSPERO) database (CRD42023417391). We searched Scopus, Web of Science, PubMed, Embase, and Cochrane Central databases.
Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China (pdf) | Paperity

May 20, 2023 | paperity.org | Siew Chin

Cost Effectiveness and Resource Allocation, Mar 2023 This is a preview of a remote PDF: https://resource-allocation.biomedcentral.com/counter/pdf/10.1186/s12962-023-00435-x Gong, Hongyu, Ong, Siew Chin, Li, Fan, Weng, Zhiying, Zhao, Keying, Jiang, Zhengyou. , Cost Effectiveness and Resource Allocation, 2023, pp. 1-12, Volume 21, Issue 1, DOI: 10.1186/s12962-023-00435-x

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →